Albert David Ltd (ALBERTDAVD) AI Stock Analysis

• Market Cap: ₹3.92B
• Dividend Yield: 0.66%
• Average Volume (3M): 210.00
• Price to Earnings (P/E): 42.1
• Beta (1Y): 1.20
• Revenue Growth: -13.51%
• EPS Growth: -122.00%
• Country: IN
• Employees: 1,497
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 26.82
• Shares Outstanding: 5,707,162
• 10 Day Avg. Volume: 184
• 30 Day Avg. Volume: 210
• PEG Ratio: -0.36
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 1.37
• P/FCF Ratio: -10.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ₹690.00 ▼(-12.48% Downside)
• Action: Reiterated Date: 11/25/25
• Date: Action: Reiterated 11/25/25

Albert David Ltd's overall stock score is primarily impacted by its strong balance sheet, which is overshadowed by declining financial performance and bearish technical indicators. The negative P/E ratio and low dividend yield further weigh on the valuation.

Positive Factors

Low leverage and strong equity base

A low debt load and robust equity ratio give the company durable financial flexibility: it can fund working capital, absorb shocks, and pursue selective capex or partnerships without immediate refinancing. That stability supports operations and strategy over the next several months.

Diversified domestic and export sales model

A dual revenue stream—branded/generic domestic channels plus exports—reduces single-market dependence and smooths demand cycles. This structural diversification supports steadier volumes and pricing over time, aiding resilience amid near-term domestic or export market shifts.

Strong gross profit margin / cost control

Sustained gross margin strength indicates disciplined input costs and manufacturing efficiency. That margin buffer helps protect operating profitability during revenue softness, preserves cash conversion potential, and provides management room to invest in high-return SKUs or market support.

Negative Factors

Declining revenue trend

A notable revenue decline reduces economies of scale, pressures fixed-cost absorption and limits reinvestment capacity. If this trend persists, it can erode market share, weaken negotiating leverage with suppliers, and constrain the company’s ability to restore top-line momentum over the medium term.

Sharp EPS deterioration

A steep drop in EPS signals material earnings stress, lowering retained earnings and reducing internal capital for R&D, marketing or working capital. Persistent earnings deterioration undermines confidence in profitability recovery and increases vulnerability to competitive or pricing pressure.

Negative operating and free cash flow

Negative operational and free cash flow creates liquidity strain despite low leverage, limiting ability to fund day-to-day needs, capex or inventory buildup. Over several months this elevates refinancing or external funding risk and reduces runway for strategic investments or margin recovery.

Albert David Ltd Business Overview & Revenue Model

Company Description

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company also exports its products to Latin American, Southeast Asian, and other African countries. The company was incorporated in 1938 and is headquartered in Kolkata, India.

How the Company Makes Money

Albert David Ltd generates revenue through multiple streams, primarily by selling its medical devices and healthcare products to hospitals, clinics, and healthcare distributors. The company engages in direct sales and also leverages partnerships with key healthcare organizations and distributors to expand its market reach. Additionally, Albert David may earn revenue through service contracts, maintenance agreements, and training programs associated with their products. The company's strategic collaborations with research institutions and healthcare providers also contribute to its earnings by facilitating product development and enhancing its market competitiveness.

Albert David Ltd Financial Statement Overview

Summary

Albert David Ltd shows a strong balance sheet with low leverage and solid equity, but faces challenges with declining revenue, profitability, and negative cash flows. These issues need addressing for sustainable growth.

Income Statement

Albert David Ltd has shown a mixed performance in terms of revenue and profitability. The gross profit margin is strong, indicating effective cost management, but the net profit margin has declined significantly in the latest year, reflecting a decrease in profitability. Revenue has shown fluctuations, with a notable decline in the most recent year, which is a concern for growth prospects.

Balance Sheet

The company's balance sheet reflects solid equity and a low level of debt, which is a positive indicator of financial stability. The equity ratio is robust, and the company has maintained a strong return on equity, although it has decreased in the latest year. The low debt-to-equity ratio limits financial risk.

Cash Flow

Cash flow from operations has turned negative in the latest year, which is a significant drawback. Free cash flow also fell into negative territory, indicating potential liquidity issues. In previous years, cash flow metrics were healthier, but the recent downturn in free cash flow growth rate raises concerns about the company's ability to generate cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.27B	3.46B	3.60B	3.42B	3.12B	2.46B
Gross Profit	2.16B	2.29B	2.32B	2.18B	1.95B	1.58B
EBITDA	-95.32M	30.26M	1.05B	598.68M	567.76M	364.59M
Net Income	62.94M	172.01M	754.20M	361.75M	352.58M	221.43M
Balance Sheet
Total Assets	0.00	5.11B	4.98B	4.23B	4.03B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.44B	2.44B	2.85B	2.03B	1.75B	1.49B
Total Debt	0.00	123.17M	33.24M	53.18M	56.62M	16.19M
Total Liabilities	-3.92B	1.19B	1.15B	1.12B	1.23B	970.20M
Stockholders Equity	3.92B	3.92B	3.83B	3.12B	2.79B	2.44B
Cash Flow
Free Cash Flow	0.00	-432.92M	346.28M	52.78M	292.83M	349.79M
Operating Cash Flow	0.00	-284.36M	455.02M	105.15M	403.65M	366.11M
Investing Cash Flow	0.00	233.01M	-332.48M	-49.95M	-396.97M	-366.84M
Financing Cash Flow	0.00	1.10M	-82.70M	-63.62M	-12.59M	-17.05M

Albert David Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 788.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 788.4 is above the 20-day moving average (MA) of 714.50, above the 50-day MA of 719.56, and below the 200-day MA of 798.24, indicating a bearish trend. The MACD of -2.50 indicates Positive momentum. The RSI at 38.43 is Neutral, neither overbought nor oversold. The STOCH value of 2.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZIMLAB	63 Neutral	₹3.34B	47.86	―	―	-5.82%	-59.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹3.92B	42.10	―	0.66%	-13.51%	-122.00%
LYKALABS	51 Neutral	₹2.17B	-331.35	―	―	4.04%	-35.02%
NECLIFE	46 Neutral	₹2.61B	-0.73	―	―	-30.27%	-3470.06%
VIKASLIFE	46 Neutral	₹2.60B	-23.10	―	―	9.42%	-12220.00%
BROOKS	45 Neutral	₹1.84B	8.53	―	―	18.67%	―

Albert David Ltd Corporate Events

Albert David to Close Trading Window Ahead of Q3 FY2025-26 Results

Albert David Limited has announced that its trading window for dealing in the company’s shares will be closed from 1 January 2026 in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct on insider trading. During this period, designated persons, insiders and their immediate relatives are barred from trading in the company’s securities, with additional controls including PAN-level freezing of designated persons’ accounts via CDSL, until 48 hours after the release of its unaudited financial results for the third quarter and nine months ended 31 December 2025; the board meeting date to consider these results will be announced separately.